BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

FDA approves BioCryst's ORLADEYO pellet for HAE prevention in adults and adolescents.

What the company is saying

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is announcing FDA approval of its supplemental New Drug Application for the 150 mg oral pellet formulation of ORLADEYO (berotralstat) as prophylactic therapy for hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The company frames this as expanding administration options for patients who have difficulty swallowing capsules or prefer pellets, emphasizing the product's flexibility and patient-centric approach. Charlie Gayer, President and CEO, characterizes the approval as a milestone that enhances personalized treatment and supports the company's commitment to optimizing HAE management. The announcement highlights ORLADEYO as the first and only targeted oral prophylactic therapy for HAE patients aged 2 and above, though this exclusivity claim is not substantiated with comparative data. The company underscores proven efficacy and safety from clinical studies, as well as the product's regulatory track record in over 45 countries. The tone is confident and positions BioCryst as a leader in rare disease therapeutics.

What the data suggests

The FDA approval is a realized milestone, immediately expanding ORLADEYO's U.S. label to include adults and adolescents for the oral pellet formulation. Clinical data show the 150 mg capsule formulation achieved a 91% mean attack-rate reduction at 96 weeks and an 88% reduction in rescue medication use in patients 12 years and older, supporting the efficacy narrative. Safety data indicate the most common adverse reactions (≥10%) were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease, with gastrointestinal events generally self-resolving over time. The approval was based on chemistry, manufacturing, and controls data demonstrating safety and tolerability of the pellet versus capsule. No financial, sales, or market uptake data are disclosed, so the commercial impact remains unquantified. The claim that ORLADEYO is the 'first and only' oral prophylactic for HAE aged 2 and above is asserted but not supported with external or comparative evidence. The reference to December 2025 FDA approval for pediatric use is not credible, as this date is in the future relative to the announcement.

Analysis

The announcement is positive in tone, highlighting FDA approval of a new oral pellet formulation of ORLADEYO for adults and adolescents. The core claims—regulatory approval, clinical efficacy, and safety—are well-supported by disclosed data. However, the release contains some inflated language, such as 'first and only targeted oral prophylactic therapy,' without comparative evidence, and references to future commercial success and market acceptance, which are inherently forward-looking and unquantified. No financial or sales data are provided, so the commercial impact is unknown. The approval is a realised milestone, but the absence of financial metrics means the investment signal cannot be rated above weak_positive. There is no indication of a large capital outlay or delayed benefit; the new formulation is available immediately for prescribing.

Risk flags

• ●Commercial uptake risk is significant, as the announcement provides no sales, revenue, or market adoption data for the new pellet formulation. Without evidence of demand or payer acceptance, the financial impact is uncertain.
• ●Regulatory and reimbursement risk persists, as the company explicitly warns that pricing, reimbursement decisions, or government actions may not occur as expected, and FDA approval could be withdrawn.
• ●Safety and drug interaction risks are present, including potential QTc interval prolongation at higher doses, moderate inhibition of CYP2D6 and CYP3A4, and reduced efficacy with P-glycoprotein inducers. These factors could limit prescribing or lead to adverse outcomes.
• ●The claim of exclusivity ('first and only' oral prophylactic for HAE aged 2 and above) is not substantiated with comparative or market data, raising reputational risk if competitors emerge or if the claim is challenged.

Bottom line

BioCryst's FDA approval for the ORLADEYO oral pellet formulation in adults and adolescents is a concrete regulatory win that broadens its product offering for HAE prevention. Clinical data support strong efficacy (91% attack-rate reduction, 88% reduction in rescue medication use), and safety is consistent with prior capsule data, though gastrointestinal side effects are common early in treatment. The approval is effective immediately, but the announcement omits any financial, sales, or market uptake figures, leaving the commercial impact unproven. Key risks include uncertain payer and patient adoption, potential regulatory or reimbursement setbacks, and unverified exclusivity claims. Investors should watch for future disclosures on sales performance and real-world uptake to assess whether this expanded label translates into meaningful revenue growth. The most important takeaway is that BioCryst has achieved a new regulatory milestone, but the economic value of this approval will depend on market execution.

Announcement summary

(NASDAQ:BCRX) BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for the oral pellet formulation of once-daily ORLADEYO (berotralstat) for prophylactic therapy in adults and adolescents aged 12 years and older. The new 150 mg ORLADEYO pellet formulation offers an alternative administration option for adults and adolescents who have difficulty swallowing, prefer not to take a capsule, or choose to remain on a pellet formulation beyond age 12. With this approval, prescribers can now offer adult and adolescent patients the option to take once-daily, orally administered ORLADEYO for prophylaxis to prevent attacks of hereditary angioedema (HAE) in either capsule or pellet formulation. The ORLADEYO pellet formulation is sprinkle-like in appearance and can be poured directly into the mouth and swallowed with water or milk, or sprinkled over a spoonful of soft, non-acidic food. Charlie Gayer, President and Chief Executive Officer of BioCryst, stated that the approval of ORLADEYO pellets for adults and adolescents strengthens the company's ability to provide personalized treatment choice and reflects a commitment to optimizing HAE management. ORLADEYO is the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and above. The capsule formulation of ORLADEYO received FDA approval for prophylaxis to prevent HAE attacks in adult and pediatric patients 12 years and older in December 2020 and is now approved in more than 45 countries. In December 2025, the oral pellet formulation was approved by FDA for prophylactic therapy in pediatric patients in the U.S. with HAE aged 2 to <12 years. Across two clinical studies, ORLADEYO capsules (150 mg) resulted in a mean attack-rate reduction of 91% at 96 weeks and an 88% reduction in rescue medication use in patients 12 years and older. ORLADEYO was safe and well tolerated in both trials, with the most frequently reported adverse reactions being gastrointestinal reactions and back pain. Gastrointestinal reactions generally occurred early after initiation of treatment, became less frequent with time, and typically self-resolved. The FDA approval was based on chemistry, manufacturing, and controls information and data demonstrating the safety and tolerability of the ORLADEYO pellet formulation compared to capsules. ORLADEYO is indicated for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 2 years and older. The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established, and it should not be used for acute attacks. Additional doses or doses higher than the prescribed once-daily dose are not recommended due to the potential for QTc interval prolongation. An increase in QTc interval was observed in adults at dosages higher than 150 mg once daily and was concentration dependent. The most common adverse reactions (≥10%) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease. In adult and pediatric patients aged 12 years and older with moderate or severe hepatic impairment (Child-Pugh B or C), the recommended dosage is 110 mg once daily with food. In pediatric patients aged 2 to <12 years with moderate or severe hepatic impairment, use of ORLADEYO should be avoided. ORLADEYO is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein, and P-gp inducers may decrease berotralstat plasma concentration, leading to reduced efficacy. ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4, and concomitant use with substrates of these enzymes can increase exposure and risk of adverse reactions. The safety and effectiveness of ORLADEYO in pediatric patients under 2 years of age have not been established. There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy, and no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

Disagree with this article?